Oncology – Head and Neck
Cohort Study: GLP1 receptor agonist use not associated with significant increase in thyroid cancer risk – The BMJ
25 May, 2024 | 19:51h | UTCA large Scandinavian cohort study investigated the association between glucagon-like peptide 1 (GLP1) receptor agonist use and thyroid cancer risk in Denmark, Norway, and Sweden from 2007 to 2021. The study compared 145,410 patients treated with GLP1 receptor agonists to 291,667 patients treated with dipeptidyl peptidase 4 (DPP4) inhibitors and included an additional analysis with sodium-glucose cotransporter 2 (SGLT2) inhibitors. Results showed no significant increase in thyroid cancer risk among GLP1 users over a mean follow-up of 3.9 years, with a hazard ratio of 0.93 (95% CI, 0.66 to 1.31) compared to DPP4 inhibitor users. The study utilized nationwide cancer registers and employed an active-comparator, new user design to minimize confounding, using Cox regression models adjusted by propensity score weighting. The findings suggest that while small risk increases cannot be definitively ruled out, the use of GLP1 receptor agonists does not substantially elevate thyroid cancer risk.
Reference (link to free full-text):
RCT | Upfront radiosurgery reduces tumor volume vs. a wait-and-scan approach in small- to medium-sized vestibular schwannoma
7 Aug, 2023 | 14:40h | UTCUpfront Radiosurgery vs a Wait-and-Scan Approach for Small- or Medium-Sized Vestibular Schwannoma: The V-REX Randomized Clinical Trial – JAMA (free for a limited period)
See also: Visual Abstract
Commentary on Twitter
Among patients with small or medium vestibular schwannoma, a treatment strategy consisting of upfront radiosurgery was more effective at reducing tumor volume at 4 years than was the initial wait-and-scan approach. https://t.co/Qv3YZVsq2Q pic.twitter.com/aNeu7MJfl0
— JAMA (@JAMA_current) August 2, 2023
Review | The evolving landscape of salivary gland tumors
27 Jul, 2023 | 12:58h | UTCThe evolving landscape of salivary gland tumors – CA: A Cancer Journal for Clinicians
RCT | Dysphagia-optimized intensity-modulated radiotherapy better preserves swallowing function in pharyngeal cancer patients
25 Jul, 2023 | 13:52h | UTCCommentaries:
Radiation approach improves swallowing in head, neck cancer – MDedge
Commentary on Twitter
NOW OF: The (DARS) phase 3 RCT investigates if dysphagia-optimised intensity-modulated radiotherapy (IMRT) reduces radiation dose to the dysphagia and aspiration related structures and improves swallowing function compared with standard IMRT.#hncsmhttps://t.co/CzpxsNxx1N pic.twitter.com/xNgfm43tHE
— The Lancet Oncology (@TheLancetOncol) July 7, 2023
TTMV-HPV DNA testing | Promising diagnostic and surveillance tool for HPV-linked oropharyngeal cancer
17 Jul, 2023 | 13:25h | UTCPerformance of Liquid Biopsy for Diagnosis and Surveillance of Human Papillomavirus–Associated Oropharyngeal Cancer – JAMA Otolaryngology–Head & Neck Surgery (free for a limited period)
Invited Commentary: Circulating Human Papillomavirus Tumor DNA—Ready for Prime Time? – – JAMA Otolaryngology–Head & Neck Surgery (free for a limited period)
2023 ETA clinical practice guidelines for thyroid nodule management
12 Jul, 2023 | 13:48h | UTC
The 2023 Bethesda System for reporting thyroid cytopathology
12 Jul, 2023 | 13:46h | UTCThe 2023 Bethesda System for Reporting Thyroid Cytopathology – Thyroid
RCT | Cisplatin–gemcitabine improves 3-year progression-free survival in N2–3 nasopharyngeal carcinoma compared to cisplatin–fluorouracil
16 Jun, 2023 | 14:05h | UTCConcurrent chemoradiotherapy followed by adjuvant cisplatin–gemcitabine versus cisplatin–fluorouracil chemotherapy for N2–3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
NOW OF: Concurrent chemoradiotherapy followed by adjuvant cisplatin–gemcitabine versus cisplatin–fluorouracil chemotherapy for N2–3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trialhttps://t.co/n6WalQiRfo pic.twitter.com/vE4VASUIgM
— The Lancet Oncology (@TheLancetOncol) June 5, 2023
Review | Updated salivary gland immunohistochemistry
5 May, 2023 | 14:55h | UTCUpdated Salivary Gland Immunohistochemistry: A Review – Archives of Pathology & Laboratory Medicine
RCT | Effects of Docetaxel as a radiosensitizer in patients with head and neck cancer, unsuitable for cisplatin-based chemoradiation
29 Mar, 2023 | 13:05h | UTCResults of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation – Journal of Clinical Oncology (link to abstract – $ for full-text)
Editorial: Good Radiosensitizer Hunting – Journal of Clinical Oncology
Commentaries:
Docetaxel Added to Radiation Provides DFS, OS Benefit in Cisplatin-Ineligible HNSCC – OncLive
RCT | Hyperfractionation vs. standard fractionation in IMRT for patients with locally advanced recurrent nasopharyngeal carcinoma
22 Mar, 2023 | 13:12h | UTCHyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Feasibility and efficacy of microwave ablation in the treatment of papillary thyroid microcarcinoma: a prospective cohort study
14 Mar, 2023 | 13:30h | UTCMicrowave Ablation for Papillary Thyroid Microcarcinoma with and without US-detected Capsule Invasion: A Multicenter Prospective Cohort Study – Radiology (link to abstract – $ for full-text)
RCT | Medial retropharyngeal nodal region sparing radiotherapy vs. standard radiotherapy in patients with nasopharyngeal carcinoma
7 Feb, 2023 | 14:09h | UTC
Salivary gland cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
27 Jan, 2023 | 12:16h | UTC
RCT | Nivolumab plus Ipilimumab vs. EXTREME regimen as first-line treatment for recurrent/metastatic head and neck cancer
19 Jan, 2023 | 13:41h | UTC
NICE Guideline | Thyroid cancer: assessment and management
11 Jan, 2023 | 14:34h | UTCThyroid cancer: assessment and management – National Institute for Health and Care Excellence
ASCO Guideline | Immunotherapy and biomarker testing in recurrent and metastatic head and neck cancers
9 Jan, 2023 | 14:41h | UTCNews Release: ASCO Publishes New Guideline on Immunotherapy, Biomarker Testing in Advanced Head and Neck Cancer – ASCO Daily News
Cohort Study | Lobectomy vs. total thyroidectomy for intermediate-risk papillary thyroid carcinoma with lymph node metastasis.
6 Dec, 2022 | 13:41h | UTCComparison of Lobectomy vs Total Thyroidectomy for Intermediate-Risk Papillary Thyroid Carcinoma With Lymph Node Metastasis – JAMA Surgery (free for a limited period)
Invited Commentary: Is Lobectomy as Effective as Total Thyroidectomy in Treating Patients With Intermediate-Risk Papillary Thyroid Carcinoma With Lateral Lymph Node Metastasis? – JAMA Surgery (free for a limited period)
Commentary on Twitter
Study of patients with papillary thyroid carcinoma and lymph node metastases found that recurrence-free survival was similar after lobectomy and total #thyroidectomy. https://t.co/07mMcczp1T
— JAMA Surgery (@JAMASurgery) December 1, 2022
Case–control study | GLP-1 receptor agonists linked to increased risk of thyroid cancer.
25 Nov, 2022 | 12:42h | UTCGLP-1 Receptor Agonists and the Risk of Thyroid Cancer – Diabetes Care (link to abstract – $ for full-text)
Commentary: GLP-1 receptor agonists associated with thyroid cancer – ACP Internist
RCT | Low-dose immunotherapy (nivolumab) may improve outcomes when added to chemotherapy for head and neck cancer.
7 Nov, 2022 | 12:26h | UTCLow-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary from the author on Twitter
Low-Dose Immunotherapy has made immunotherapy more accessible, and has brought down the cost of therapy from 60-80 lakhs to below 5.0 lakhs per year. Hugh cost saving. A step towards atmanirbhar Bharat. @PMOIndia @TOIIndiaNews @ndtv @ZeeNews @the_hindu https://t.co/c0WuC9Wlfk
— Dr. Vijay Patil (@DrVijayPatil11) October 21, 2022
2022 ETA Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma.
27 Oct, 2022 | 12:33h | UTCCommentary: New EU Guidelines: Individualize Care for Thyroid Cancer in Kids – Medscape (free registration required)
RCT | Adjuvant capecitabine following concurrent CTX-RT in locoregionally advanced nasopharyngeal carcinoma.
17 Oct, 2022 | 12:15h | UTC
4-year follow-up of a RCT | Pembrolizumab with vs. without chemotherapy in recurrent or metastatic head and neck SCC.
14 Oct, 2022 | 14:11h | UTCOriginal Study: Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study – The Lancet (link to abstract – $ for full-text)
Guideline Summary | Recommendations for care of survivors of head and neck cancer.
7 Oct, 2022 | 14:15h | UTCRecommendations for Care of Survivors of Head and Neck Cancer – JAMA (free for a limited period)
Original Guideline: Head and neck cancer survivorship consensus statement from the American Head and Neck Society – Laryngoscope Investigative Otolaryngology
Related:
American Cancer Society Head and Neck Cancer Survivorship Care Guideline
RCT | Selumetinib plus adjuvant radioactive iodine in patients with high-risk differentiated thyroid cancer.
3 Oct, 2022 | 13:42h | UTCCommentary: Selumetinib Does Not Improve CR Rate in Differentiated Thyroid Cancer – Cancer Therapy Adviser
Commentary on Twitter
❎ ASTRA trial: Radioactive iodine ± selumetinib doesn't improve remission rates for high-risk #thyroidcancer
✅ Postoperative pathologic risk stratification identified pts at risk of primary treatment failurehttps://t.co/kvakaMXtDh#JCO #thycsm @MSKCancerCenter pic.twitter.com/mvQwgzIjWh— Journal of Clinical Oncology (@JCO_ASCO) March 16, 2022